Core Scientific annual free cash flow
2020
2021
2022
2023
2024
2025
Core Scientific Free Cash Flow (FCF) History (CORZ)
Core Scientific reported −$450.8M in free cash flow for fiscal 2025, a decrease of $398.7M from the previous fiscal year, with a free cash flow margin of −141.29%.
View full Core Scientific company overviewCore Scientific free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$450.8M | −$398.7M | — | −141.29% |
| 2024 | 2024-12-31 | −$52.1M | −$101.0M | — | −10.20% |
| 2023 | 2023-12-31 | $49.0M | $227.7M | — | +9.74% |
| 2022 | 2022-12-31 | −$178.8M | −$122.1M | — | −27.92% |
| 2021 | 2021-12-31 | −$56.7M | −$33.0M | — | −10.42% |
| 2020 | 2020-12-31 | −$23.8M | — | — | −39.40% |
Core Scientific quarterly free cash flow
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$583.9M | −$496.7M | — | −355.63% |
| Q1 2026 | 2026-03-31 | −$139.3M | −$10.3M | — | −120.92% |
| Q4 2025 | 2025-12-31 | −$121.7M | −$106.8M | — | −152.62% |
| Q3 2025 | 2025-09-30 | −$112.7M | −$87.3M | — | −138.97% |
| Q2 2025 | 2025-06-30 | −$87.3M | −$85.3M | — | −111.00% |
| Q1 2025 | 2025-03-31 | −$129.0M | −$119.3M | — | −162.24% |
| Q4 2024 | 2024-12-31 | −$15.0M | −$25.0M | — | −15.75% |
| Q3 2024 | 2024-09-30 | −$25.5M | −$28.2M | — | −26.70% |
| Q2 2024 | 2024-06-30 | −$1.9M | −$19.7M | — | −1.37% |
| Q1 2024 | 2024-03-31 | −$9.7M | −$28.1M | — | −5.42% |
| Q4 2023 | 2023-12-31 | $10.1M | $34.3M | — | +7.09% |
| Q3 2023 | 2023-09-30 | $2.7M | $60.0M | — | +2.38% |
| Q2 2023 | 2023-06-30 | $17.8M | −$21.8M | −55.02% | +14.03% |
| Q1 2023 | 2023-03-31 | $18.4M | $155.2M | — | +15.25% |
| Q4 2022 | 2022-12-31 | −$24.2M | −$17.9M | — | −19.98% |
| Q3 2022 | 2022-09-30 | −$57.3M | $64.8M | — | −35.25% |
| Q2 2022 | 2022-06-30 | $39.6M | $204.6M | — | +24.13% |
| Q1 2022 | 2022-03-31 | −$136.8M | −$141.5M | — | −71.08% |
| Q4 2021 | 2021-12-31 | −$6.3M | — | — | −2.10% |
| Q3 2021 | 2021-09-30 | −$122.1M | — | — | −107.96% |
| Q2 2021 | 2021-06-30 | −$165.1M | — | — | −219.20% |
| Q1 2021 | 2021-03-31 | $4.7M | — | — | +8.58% |
Core Scientific free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$23.8M to −$450.8M, a net decrease of $427.0M. Core Scientific's latest reported quarter, Q2 2026, generated −$583.9M in free cash flow, a decrease of $496.7M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Core Scientific filings at SEC.gov ↗